Natural product-based therapy for Visceral pain: Cucurbitacin I (JSI-124) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 10.01 am

Natural product-based therapy for Visceral pain: Cucurbitacin I (JSI-124) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 10.01 am

Natural product-based therapy for Visceral pain: Cucurbitacin I (JSI-124) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 10.01 am 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, Natural product-based therapy for Visceral pain: Cucurbitacin I (JSI-124) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 10.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Cucurbitacin I, by increasing the expression of its target gene, it may decrease visceral pain in patients with Irritable Bowel Syndrome.  Thus, pharmacological formulations encompassing ” Cucurbitacin I or its analogues“  may be used to treat visceral pain.

Amount: $ 500*

Undisclosed information: How   Cucurbitacin I decreases visceral pain

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
Start Typing